United BioPharma (UBP) today announced their latest results featuring unprecedented and unique functional characteristics of UB-221 monoclonal...
TAIPEI, May 29, 2022 /PRNewswire/ -- Taiwan-based United BioPharma (UBP) has announced the approval of a Phase 2 clinical trial with novel anti-IgE monoclonal antibody UB-221 by the Taiwan Food and Drug Administration (TFDA).
TAIPEI, Oct. 18, 2021 /PRNewswire/ -- United BioPharma announced today that Shanghai Public Health Clinical Centre and Cheng Kung University's Department of Microbiology and Immunology have joined United BioPharma's fight against the global herpes endemic. Together with United BioPharma, the two institutions will test the effectiveness of UB-621, a best-in-class long-acting treatment for genital herpes caused by simplex viruses 1 and 2 (HSV 1 and HSV2) in preparation for phase II trials in the United States and China.
Taipei, Taiwan – November 10th, 2020 –United BioPharma (UBP) announced today that they have received Investigational New Drug (IND) approval from China National Medical Products Administration (NMPA) to conduct a Phase 2 clinical trial with UB-621, an anti-HSV (Herpes Simplex Virus) monoclonal antibody, to evaluate its safety and efficacy in adults with recurrent genital herpes.